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Abstract 
Background: Peanut sensitization does not necessarily indicate clinical peanut allergy, and uncertainty as to whether 
or not there is true peanut allergy can lead to increased anxiety and decreased quality of life for patients and their 
families. The gold standard for diagnosing clinical peanut allergy is the oral food challenge, but this method is time-
consuming and can cause severe allergic reactions. It would therefore be beneficial to develop a tool for predicting 
clinical peanut allergy in peanut-sensitized individuals whose peanut allergy status is unknown so as to better deter-
mine who requires an oral food challenge for diagnosis.
Methods: Two separate studies were conducted. In Study 1, we recruited 100 participants from the allergy clinic at 
McMaster University and community allergy outpatient clinics in the greater Hamilton area. We examined 18 differ-
ent variables from participants and used univariate and multivariable logistic regression analysis to determine how 
well these variables, singly and in combination, were able to predict clinical peanut allergy status. In Study 2, we 
conducted a retrospective chart review of a second cohort of 194 participants to investigate the reproducibility of 
our findings. This was a matched case–control study where 97 peanut-allergic participants were gender- and age-
matched to 97 non-allergic control participants.
Results: Peanut skin prick test wheal size was the best predictor of clinical peanut allergy in both study cohorts. For 
every 1 mm increase in wheal size, the odds ratio of an individual having clinical peanut allergy was 2.36 in our first 
cohort and 4.85 in our second cohort. No other variable approached the predictive power of wheal size.
Conclusions: Peanut skin prick test wheal size is a robust predictor of clinical peanut reactivity. The findings of this 
study may be useful in guiding clinician decision-making regarding peanut allergy diagnostics.
Keywords: Peanut allergy, Skin prick test, Wheal size
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Peanut allergy is a serious public health concern, espe-
cially in westernized countries. Its prevalence has 
doubled in the past 10  years and currently stands at 
approximately 2% [1].
Peanut allergy is diagnosed by combining clinical his-
tory with diagnostic methods that may include skin-prick 
tests (SPT) and serum IgE measurements to peanut [2]. 
Many parents have avoided feeding their children peanut 
in an attempt to prevent peanut allergy, yet many chil-
dren have developed sensitization to peanut, as demon-
strated by a positive peanut SPT or peanut-specific IgE, 
and continue to avoid peanut. However, peanut sensiti-
zation does not necessarily mean clinical peanut allergy, 
and uncertainty as to whether or not there is true peanut 
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allergy can lead to increased anxiety and decreased qual-
ity of life for patients and their families. The gold stand-
ard for diagnosing clinical peanut allergy is the oral 
food challenge, but this method is time consuming and 
requires proper set-up and personnel to manage poten-
tial severe allergic reactions [3]. Therefore, it would be 
beneficial to develop a tool for predicting clinical peanut 
allergy in peanut-sensitized individuals whose peanut 
allergy status is unknown so as to better determine who 
requires an oral food challenge for diagnosis.
The goal of this study was to use clinical and labora-
tory data from patients of known peanut allergy status 
to develop a statistical model to predict clinical peanut 
allergy in peanut-sensitized individuals. To determine 
its predictive merit, the model was applied to a group of 
patients with positive skin prick tests, but unknown clini-
cal reactivity because they had never knowingly ingested 
peanut. These patients of unknown clinical status then 
underwent an oral peanut challenge to determine their 
true peanut allergy status and this outcome was com-
pared to their model-predicted peanut allergy status.
Methods
Study 1: patient recruitment and data collection
100 participants were recruited from the allergy clinic at 
McMaster University and community allergy outpatient 
clinics in the greater Hamilton area.
All participants were at least 6 years of age and of either 
sex. Exclusion criteria for the study were uncontrolled or 
severe asthma, receipt of allergy injections in the past, 
and use of injectable epinephrine 1  month prior to the 
start of the study. Individuals taking daily antihistamines, 
leukotriene receptor antagonists, or nasal, inhaled, or 
oral corticosteroids were also excluded. These interven-
tions may have interfered with our study measurements, 
particularly cytokine secretion.
We collected the following data on each participant: 
age, sex, peanut SPT wheal size, clinical peanut allergy 
status, peanut ImmunoCAP, total IgE, supernatants 
from peripheral blood mononuclear cells (PBMC) under 
unstimulated and peanut-stimulated conditions, immedi-
ate family history of peanut allergy, asthma, rhinitis, and 
eczema status.
Participants were divided into 4 groups according to 
their peanut allergy status based on history and peanut 
skin prick test.
Group 1 consisted of peanut allergic individuals. These 
individuals had a prior history of an allergic reaction to 
peanut on ingestion and a positive SPT to peanut. Aller-
gic symptoms included, but were not limited to, urticaria, 
angioedema, dyspnea, cough, wheeze, nausea, vomiting, 
lightheadedness, rash, and/or shock.
Group 2 consisted of individuals who had a positive 
skin prick test to peanut, but could tolerate peanut inges-
tion without difficulty. Thus, these individuals were not 
allergic to peanut and their skin test results were desig-
nated as “false positives”.
Group 3 consisted of individuals who had a positive 
skin prick test, but no known history of peanut inges-
tion. Many of these individuals may have avoided peanut 
for specific reasons, such as a family history of peanut 
allergy. It was therefore uncertain whether they would 
react to peanut on ingestion and they were considered to 
be at risk of clinical reactivity based on the presence of 
sensitization.
Group 4 consisted of individuals who had a negative 
skin prick test to peanut and had previously ingested 
peanut without problems. Consequently, they served as a 
negative control group. This group did not have any other 
food or environmental allergies.
This study was approved by the Research Ethics Board 
at McMaster University and all participants, or their 
guardians, provided written informed consent.
Skin prick test measurements
The forearm was prepped with alcohol and peanut 
extract (ALK-Pharmaceuticals, Mississauga, ON, Can-
ada) was applied to the skin of the dorsal forearm. A 
sterile metal lancet (HollisterStier, Spokane, WA, USA) 
was used to puncture the skin below the allergen drop-
let. Skin prick test wheal size was measured after 15 min. 
Tape was placed on the dorsal forearm and an outline of 
the wheal was traced. The widest diameter of the wheal 
was measured by two different study nurses.
Peanut and total IgE plasma measurements
Total IgE was measured using the Immage 800 (Beck-
man Coulter, Mississauga, ON, Canada) and peanut-spe-
cific IgE antibodies were measured using the Phadia 250 
(Thermo Scientific, Waltham, MA, USA).
Cytokine measurements
Mononuclear cells were isolated from 30 to 40  ml of 
blood by density gradient centrifugation after red blood 
cells were lysed with AKC lysis buffer. Cells were re-
suspended in RPMI supplemented with 10% FBS, 1% 
l-glutamine, 1% penicillin/streptomycin, 55  µM 2-mer-
captoethanol (Thermo Scientific), 1  mM sodium pyru-
vate, 10 mM HEPES and 0.1 mM MEM NEAA (Thermo 
Scientific). Viable cells were counted via Trypan Blue 
(Thermo Scientific) exclusion and re-suspended at 
8 × 106 cells/mL. 125,000 live cells per well were cultured 
in triplicates in medium alone or with 50 µg/mL/well of 
crude peanut extract in flat-bottom 96-well plates (BD 
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Biosciences, Mississauga, ON, Canada). After 5  days of 
culture at 37 °C and 5% CO2, the triplicates were pooled, 
spun down and cell-free supernatants harvested and 
stored at −80 °C until further analysis. Cytokines in cell-
free supernatants were quantified using Luminex (Milli-
pore Canada Ltd, Etobicoke, ON, Canada) following the 
manufacture’s instructions.
Statistical analysis
Each predictor was entered into a univariate logistic 
regression analysis to determine if it was associated with 
the primary outcome—clinical peanut allergy status. We 
then generated cumulative models composed of multiple 
predictors using multivariable logistic regression. All uni-
variate and multivariable analyses included the 69 study 
participants from Groups 1, 2, and 4.
For all models, parameter estimates were obtained for 
each predictor and expressed as odds ratios with corre-
sponding 95% confidence intervals and associated p val-
ues. p values are reported to 4 decimal places.
Hierarchical models were compared to determine if 
the model with the greater number of predictors was 
statistically significantly better at predicting the primary 
outcome than the model with fewer predictors. This 
was done by comparing the models’ −2 Log Likelihood 
statistics. For each model, the area under the Receiver 
Operating Characteristics (ROC) curve was reported as 
a measure of discriminability. The best model was used to 
predict the peanut allergy status of participants in Group 
3 and to determine the predicted probability (Pr) of each 
participant having clinical peanut allergy. Using Pr, we 
classified each individual as having a peanut allergy or 
not based on a specific cutpoint. We chose this cutpoint 
to eliminate false negatives and maximize true positives 
in the data set.
All analyses were conducted in SAS version 9.4.
Peanut challenges
All individuals in Group 3 underwent a peanut challenge 
to determine peanut allergy status. The food challenge 
took place in the Allergy Clinic at McMaster University 
Medical Centre under the supervision of a study physi-
cian. A research/Critical Care nurse and study physician 
were present at all times with the appropriate set-up to 
deal with any and all allergic reactions.
All subjects had baseline vital signs taken, body weight 
measured, and an intravenous inserted prior to oral food 
challenge.
Each subject was given either 1 mg of peanut or placebo 
orally mixed with grape jelly or applesauce. Peanut flakes 
were the source of peanut and cracker crumbs were used 
as the placebo. The dose of peanut was increased to 5 mg 
and increased every 15–30  min to 10, 25, 50, 100, 250, 
500 mg, 1, and 2.5 g until the maximum dose of 2.5 g was 
reached or objective findings of allergic reaction were 
observed. 2.5 g is the equivalent of 5 peanuts.
Subjects were carefully observed for the following 
signs of allergic reaction: rash (erythema, morbilliform 
rash, urticaria, angioedema), ocular (conjunctival swell-
ing, scleral edema, tearing), nasal (congestion, rhinor-
rhea, sneezing), respiratory (wheezing, cough, drop of 
PEF or FEV1 by >20%), gastrointestinal (vomiting, diar-
rhea, abdominal pain), systemic (blood pressure drop by 
>20%).
Vital signs (oxygen saturation, blood pressure, heart 
rate, respiratory rate) were assessed before each dose, 
with every new symptom reported, and when objective 
findings were observed.
If a subject developed any two mild symptoms (gen-
eralized itchiness or flushing, runny nose, watery eyes, 
or sneezing) or any one severe symptom (persistent 
cough, significant abdominal pain, nausea, vomiting, 
diarrhea, swelling of the lips or face, difficulty breath-
ing, wheezing, or fainting) the challenge was imme-
diately stopped and the subject was considered to be 
peanut allergic [4].
Subjects who experienced allergic reactions were 
treated with appropriate medications, namely intra-
muscular epinephrine, intravenous antihistamines, and 
corticosteroids (1  mg/kg for 3  days). The subjects were 
observed for 4–8 h after an allergic reaction to ensure that 
it had been adequately treated and resolved [5].
If 2.5 g of peanut was tolerated, 10 g was administered 
in an open challenge and subjects were monitored for 
signs of allergic reaction. In the event of a reaction, each 
subject received appropriate medication and monitoring.
The results of the oral peanut challenges were then 
compared to patients’ predicted peanut allergy status.
Study 2: patient recruitment and data collection
We conducted a retrospective chart review of a separate 
cohort of 194 subjects: 97 with confirmed clinical pea-
nut allergy, and 97 sex- and age-matched controls with-
out clinical peanut allergy. Peanut allergy was defined 
as: the participant had consumed peanuts in the past 
and displayed peanut allergy-compatible symptoms, as 
described earlier, and had undergone confirmatory test-
ing. For each participant, we collected date of birth, sex, 
peanut skin prick test wheal size, allergic rhinitis, asthma, 
and eczema status. We also recorded food allergy status 
for milk, egg, wheat, individual nut, and nut mix.
Statistical analysis
The predictive value of each variable was analyzed using 
exact conditional logistic regression. All analyses were 
conducted in SAS version 9.4.
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Results
Study 1: participant characteristics
A total of 100 subjects participated in this study and a 
summary of their characteristics is displayed in Tables 1, 
2. Half of the participants were female, 14% had an 
immediate family member (parent or sibling) with a pea-
nut allergy, and 59% had a comorbid allergic condition 
(asthma, rhinitis, or eczema). The median age in years 
was 15.5, but there was an imbalance in age between 
Groups 1, 2, and 4 versus Group 3. In Group 3 the 
median age was 9, whereas the median age of Groups 1, 
2, and 4 was 21.
Predictive values of individual variables
For the 69 participants in Groups 1, 2, and 4, each of 
18 predictor variables was entered as a single predictor 
of the primary outcome—clinical peanut allergy status. 
Nine variables were selected for entry into the multivari-
able model based on a univariate p value <0.1 (Table 3). 
All other variables evaluated had a p value >0.1. Using 
area under the ROC curve (AUC) as a measure of dis-
criminability between peanut allergic and non-peanut 
allergic participants, peanut SPT wheal size was the best 
univariate predictor, with AUC = 0.927. In other words, 
peanut SPT wheal size was the variable most able to 
accurately predict true clinical peanut allergy. A larger 
wheal size was associated with a stronger risk of clinical 
peanut allergy: the odds ratio for each 1 mm increase in 
wheal size was 2.36.
Generation of predictive models
The results of the univariate analyses revealed that peanut 
skin prick test wheal size was the strongest single predic-
tor of peanut allergy status among all variables assessed. 
The area under the ROC curve for wheal size was sig-
nificantly better than any other single predictor. Next, we 
entered wheal size into the model and added each of the 
remaining variables one at a time in a stepwise process. 
We found that rhinitis significantly improved the model 
by increasing the area under the ROC curve and improv-
ing the model’s ability to predict true peanut allergy. Fol-
lowing the same strategy, we found that asthma was the 
only remaining predictor that was statistically significant 
when added to the model. We called this combination 
of peanut wheal size, rhinitis, and asthma “Model 1”. No 
other predictors were significant (p < 0.1) when added to 
Model 1. In Model 1, wheal size and asthma were posi-
tively related to peanut allergy status, but rhinitis was 
Table 1 Study groups
Y = confirmed clinical peanut allergy; N = confirmed not allergic to peanut; 
U = unknown











Y N U N
Positive skin 
prick test to 
peanut
Y Y Y N
Table 2 Clinical characteristics
All other entries are n (%)
a Entries are mean (standard deviation)
Variable Groups 1 (n = 30) Group 2 (n = 17) Group 3 (n = 31) Group 4 (n = 22)
Age (y)a 14.17 (6.20) 25.82 (16.00) 10.16 (3.12) 36.23 (10.82)
Wheal size (mm)a 7.50 (3.35) 3.97 (1.15) 5.48 (1.91 0 (0)
Sex (F) 14 (47) 11 (65) 10 (32) 15 (68)
Father with allergy 0 (0) 0 (0) 1 (3.2) 0 (0)
Mother with allergy 2 (2.9) 0 (0) 1 (3.2) 0 (0)
Sibling with allergy 2 (7) 1 (6) 8 (26) 0 (0)
Asthma 18 (60) 5 (29) 17 (55) 0 (0)
Rhinitis 11 (37) 12 (71) 8 (26) 0 (0)
Eczema 9 (30) 0 (0) 13 (42) 0 (0)
Table 3 Univariate logistic regression analysis of  peanut 
allergy predictors
n = 69
Variable OR [95% CI] p value AUC
Wheal size 2.362 [1.533, 3.639] <0.0001 0.927
Peanut IgE 1.083 [1.021, 1.149] 0.0080 0.812
Total IgE 1.001 [0.999, 1.002] 0.0749 0.822
Gender (M) 2.286 [0.859, 6.082] 0.0978 0.600
Asthma (Y) 10.199 [3.105, 33.511] 0.0001 0.736
IL-13 (P) 1.002 [1.000, 1.003] 0.0138 0.729
IL-5 (M) 1.000 [0.999, 1.002] 0.4921 0.539
IL-5 (P) 1.002 [1.001, 1.004] 0.0040 0.696
IL-9 (P) 1.0012 [0.9999, 1.003] 0.0621 0.650
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curiously protective. The AUC for model 1 was 0.962, 
demonstrating an improvement in prediction over any 
single variable analyzed above. Table 4 shows the results 
of this model. The ROC curve for Model 1 is shown in 
Fig. 1.
Using model 1 to predict clinical peanut allergy status 
in group 3
Applying Model 1 to Group 3 generated a probabil-
ity of peanut allergy (Pr) for each of the 31 participants 
with a positive skin prick test but unknown clinical pea-
nut allergy status. We chose a cutpoint value for Pr that 
would minimize false negatives and maximize true posi-
tives, thereby maximizing the model’s ability to predict 
true peanut allergy. Using a cutpoint of 0.35 for Pr, we 
classified participants into two groups: if Pr ≥  0.35, the 
individual was predicted to have a peanut allergy, and if 
Pr < 0.35, the individual was predicted to not have a pea-
nut allergy. When predicted peanut allergy status was 
cross tabulated with known peanut allergy status based 
on peanut challenge, Model 1 predicted Group 3 peanut 
allergy status well, but made four errors. It predicted a 
negative result (NOT allergic to peanuts) for two partici-
pants whose oral food challenge indicated they did have 
clinical peanut allergy. One of these subjects had a wheal 
size equal to 5 mm, and the other had a wheal size equal 
to 6 mm. It also predicted a positive result for two partic-
ipants who did not have an oral food challenge reaction.
We then removed asthma from the model in order 
to examine whether sensitivity would improve. In our 
study, we defined sensitivity as the proportion of patients 
with a known peanut allergy who the model correctly 
predicts as having a peanut allergy. We called this new 
model comprised of only wheal size and rhinitis “Model 
2” and used it to predict Group 3 peanut allergy status. 
Model 2 proved to have a sensitivity of 100%, as it cor-
rectly predicted every participant with a known peanut 
allergy as having clinical peanut allergy. However, only 
four of seven participants with known negative peanut 
allergy status were correctly predicted as having no clini-
cal allergy, indicating a specificity of 57.1% (Table 5). We 
defined specificity as the proportion of patients with a 
known negative peanut allergy status who the model cor-
rectly predicts as not having a peanut allergy. Three par-
ticipants with known negative peanut allergy status were 
incorrectly predicted to have a peanut allergy. We believe 
this is an acceptable type of error, as it does not carry the 
same risk as classifying an allergic subject as non-allergic. 
The wheal sizes of these three participants were 3, 4 and 
5 mm.
When applied to Group 3, Model 2 (using a cutpoint of 
0.35) correctly predicted the clinical peanut allergy sta-
tus of 24/24 allergic individuals, indicating a sensitivity of 
100%.
Study 2: evaluating the predictive value of wheal size 
and allergic rhinitis status in a second patient cohort
We conducted a retrospective chart review of 97 partici-
pants with confirmed clinical peanut allergy and 97 sex- 
and age-matched control participants without clinical 
peanut allergy. Their clinical characteristics are summa-
rized in Tables 6, 7.
We classified allergic and non-allergic subjects accord-
ing to wheal size (Table 8).
Table 4 Multivariable logistic regression results for model 1
n = 69
Variable OR [95% CI] p value
Wheal size 2.606 [1.517, 4.477] 0.0005
Rhinitis (Y) 0.084 [0.010, 0.688] 0.0209
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Fig. 1 Model 1 receiver operating curve










Positive 24 (100) 3 (42.9) 27 (87.1)
Negative 0 (0) 4 (57.1) 4 (12.9)
Total 24 7 31
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We analyzed the predictive value of each variable 
using exact conditional logistic regression. This analy-
sis revealed a linear dependency among variables when 
wheal size was entered into the model. Because of this, 
we were unable to obtain a parameter estimate for wheal 
size.
We then analyzed the predictive value for each of the 
predictor variables using exact simple logistic regression 
(Table  9). We found wheal size to be the best predictor 
of clinical peanut allergy, with an odds ratio of 4.85 for 
every 1  mm increase in wheal size. The area under the 
ROC curve was 0.995, with a p value of  <0.0001. The 
predictive value of wheal size was so dominant that no 
other variable was statistically significant when added to 
a model that included wheal size.
We then examined the sensitivity and specificity of 
wheal size at different cutpoints, ranging from 1 mm to 
5 mm (Table 10). Sensitivity reached 100% at 1 mm, while 
specificity reached 100% at 5 mm.
Discussion
In Study 1 we analyzed the ability of eighteen different 
variables, alone and in combination, to predict clini-
cal peanut allergy in peanut-sensitized individuals. Our 
results show that peanut SPT wheal size is by far the best 
predictor of peanut allergy. While the univariate analy-
sis identified peanut-specific IgE, total IgE, male sex, 
asthma, and IL-5, IL-9 and IL-13 responses to peanut as 
being significant predictors of clinical reactivity, subse-
quent multivariable analyses found these variables to be 
related to peanut SPT wheal size and thus when entered 
into a model with wheal size were non-significant.
The analysis of our initial patient cohort revealed pea-
nut SPT wheal size as the best univariate predictor, with 
an AUC of 0.927. For every 1 mm increase in wheal size, 
the odds ratio of an individual having a clinical peanut 
allergy was 2.36.
In this cohort, wheal size was positively associated with 
peanut allergy status while the presence of rhinitis was 
Table 6 Participant demographics
Variable Peanut allergic Non-peanut allergic
Age in years [mean (SD); 
min, max]
9.87 (4.46); 3.00, 20.90 9.86 (4.45); 3.10, 20.80
Wheal size in mm [mean 
(SD); min, max]
8.62 (4.00); 2.00, 20.00 0.28 (0.97); 0.00, 5.00
Female sex [n (%)] 47 (48.5) 47 (48.5)
Table 7 Clinical characteristics
All entries are n(%) for affirmative
Variable Peanut allergic Non-peanut allergic
Allergic rhinitis status 57 (58.8) 54 (55.7)
Non-allergic rhinitis status 4 (4.1) 7 (7.2)
Asthma status 43 (44.3) 22 (22.7)
Eczema status 27 (27.84) 26 (26.80)
Egg sensitization 9 (9.28) 7 (7.22)
Milk sensitization 2 (2.06) 10 (10.31)
Wheat sensitization 1 (1.03) 0 (0)
Nut sensitization 33 (34.02) 13 (13.40)
Nut mix sensitization 19 (19.59) 7 (7.22)
Table 8 Peanut skin prick test wheal size by peanut allergy 
status
Wheal size (mm) Clinical peanut allergy status
No Yes Total
0 89 0 89
1 0 0 0
2 1 1 2
3 4 4 8
4 2 7 9
5 1 8 9
≥6 0 77 77
Total 97 97 194
Table 9 Exact simple logistic regression univariate analy-
sis
Variable Odds ratio [95% 
CI]
p value −2 Log L Area 
under ROC
Wheal size 4.85 [2.859, 11.44] <0.0001 33.306 0.995
Rhinitis 1.13 [0.618, 2.086] 0.7717 268.752 0.515
Non-allergic 
rhinitis
0.55 [0.115, 2.270] 0.5368 268.063 0.515
Eczema 1.05 [0.533, 2.082] 1.0000 268.915 0.505
Egg allergy 1.31 [0.415, 4.345] 0.7950 268.668 0.510
Milk allergy 0.18 [0.019, 0.901] 0.0329 262.767 0.541
Nut allergy 3.31 [1.548, 7.444] 0.0012 257.237 0.603
Nut mix 
allergy
3.11 [1.176, 9.248] 0.0191 262.329 0.562
Table 10 Sensitivity and specificity for wheal size cut-offs
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curiously protective. Using Model 2, that included both 
wheal size and rhinitis, we were able to successfully pre-
dict the clinical peanut allergy status of 100% of allergic 
subjects. However, the model misclassified three non-
allergic subjects as allergic.
Interestingly, rhinitis was found to be protective against 
clinical peanut allergy in our first group of subjects. 
However, we were unable to reproduce this finding in 
our second patient cohort. To our knowledge, there are 
no other studies in the literature reporting a similar pro-
tective effect of allergic rhinitis in peanut allergy. This 
unexpected finding may have been an anomalous result 
caused by a small patient cohort size.
The strong predictive value of wheal size emerged in 
the analysis of our much larger second patient cohort. 
We found that for every 1 mm increase in wheal size, the 
odds ratio of an individual having clinical peanut allergy 
was 4.85. No other variable approached the predictive 
power of wheal size.
Other models of clinical peanut allergy prediction, such as 
The Cork Southampton Predictive Index [6], have used pea-
nut SPT, serum specific IgE, total IgE, sex, and age to predict 
clinical peanut allergy. However, our data sets did not iden-
tify any variables that could reproducibly improve on the 
predictive ability of SPT wheal size in our patient cohorts.
The strong association between SPT wheal size and 
clinical peanut allergy has been described elsewhere. 
The HealthNuts longitudinal food allergy study in Mel-
bourne, Australia, reported that a wheal size of 8 mm had 
95% positive predictive value for clinical peanut allergy in 
1-year-old infants [7]. Decreasing wheal size was associ-
ated with peanut allergy resolution in these patients at 
age 4, while increasing wheal size was associated with 
persistence [8]. Other groups have reported wheal size 
cut-points from 4 to 15  mm reaching 100% specificity 
when used to predict clinical peanut allergy [9, 10].
The skin prick test does produce false positive results 
that can lead to misclassification of non-allergic patients 
as allergic. False positive results emerged in our study, 
and have been reported previously [9, 11, 12]. Food 
allergy misdiagnosis negatively impacts the quality of life 
of patients and their families to the same degree as true 
peanut allergy. Heightened anxiety associated with eat-
ing, disruption of daily activities, and the need to carry 
an epinephrine auto-injector is common to both groups 
[13]. However, it is our strong belief that it is never 
acceptable to misclassify an allergic patient as non-aller-
gic, especially in the context of a potentially severe diag-
nosis such as peanut allergy. A sensitive screening test, 
such as the SPT, is preferable to one that sacrifices sensi-
tivity in favour of specificity.
One potential weakness of this study is the restricted 
range of variables it examined. Specifically, we did not 
include component testing or the basophil activation 
test, both of which are emerging tools in the field of food 
allergy research [14–19]. At the time of the study these 
tests were not available to us. Additionally, they are not 
without limitations and are not currently the standard of 
care in peanut diagnostics.
Component resolved IgE testing for Ara h 1, 2, and 3 
has been highlighted as more predictive of clinical allergy 
than whole peanut-specific IgE, and sensitization to Ara 
h 2 emphasized as particularly discriminatory. However, 
there is a lack of consensus on appropriate component 
testing cutoffs and sensitivity and specificity measures of 
different cutpoints vary widely between studies. Reported 
sensitivity for a commonly used cutpoint of 0.35 kU/L 
ranges from 60 to 100% and specificity ranges from 72 
to 96%. Beyer et al. [15] described a 90% probability for 
positive peanut challenge at 14.4 kU/L, and a cutpoint of 
42.2 kU/L was required to reach a 95% probability. Addi-
tionally, the importance of individual components varies 
regionally, testing lacks standardization across commer-
cial kits, and individual patient outcomes can deviate 
from component-associated correlations [20].
The basophil activation test has been proposed as a 
useful diagnostic tool for peanut allergy, but its broad 
utility is limited by its requirement for fresh blood 
and variability in basophil activity between individu-
als [21]. As with component testing, the cost of the 
basophil activation test limits its use in routine clinical 
practice.
The comprehensive statistical analyses used in this 
study consistently highlighted the superior ability of pea-
nut SPT wheal size to predict clinical reactivity to pea-
nut. SPT wheal size emerged as the dominant predictor 
of peanut allergy in both univariate and multivariable 
analyses in two separate patient cohorts. Our statistical 
analyses also determined that the predictive power of IgE 
laboratory measurements, both total and peanut-spe-
cific, were not independent of wheal size. This was also 
true for peanut-induced Th2 cytokine production from 
peripheral blood mononuclear cells. When added to any 
statistical models containing wheal size, the predictive 
power of all laboratory measurements became statisti-
cally non-significant. As such, the power of peanut SPT 
wheal size to predict clinical peanut allergy was domi-
nant and reproducible.
Conclusions
Peanut skin prick test wheal size is a robust predictor of 
clinical peanut reactivity. We have found that patients 
with a wheal size of <1 mm do not display clinical peanut 
allergy and patients with wheal sizes  ≥6  mm are clini-
cally reactive. In patients with wheal sizes between 1 and 
5 mm inclusive, oral food challenge may be appropriate 
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to determine allergic status if history is indeterminate. 
Further studies of a large cohort of patients with wheal 
sizes in this range may be warranted. The findings of this 
study may be useful in guiding clinician decision-making 
regarding peanut allergy diagnostics.
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